PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
EBIT growth of 22.68% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
22.68%
Operating income growth of 22.68% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
22.99%
Net income growth of 22.99% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
38.32%
EPS growth of 38.32% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
38.32%
Diluted EPS growth of 38.32% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
24.80%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
24.80%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
22.87%
OCF growth of 22.87% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
22.60%
FCF growth of 22.60% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
19.53%
OCF/share CAGR of 19.53% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
73.45%
3Y OCF/share growth of 73.45% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-5088.50%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
66.11%
Net income/share CAGR of 66.11% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
78.36%
3Y net income/share CAGR > 1.5x Biotechnology median of 2.50%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
2877.65%
Equity/share CAGR of 2877.65% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
75.50%
5Y equity/share CAGR of 75.50% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-75.29%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-36.19%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-16.18%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.